Abstract
Among angiogenic peptides, vascular endothelial growth factor (VEGF) is associated with growth and metastasis of solid tumours. In order to determine whether VEGF could be involved in the clinical course of malignant melanoma, we studied 96 patients with primary or metastatic melanoma and we reported the follow-up of nine cases who initially presented with a primary melanoma and further developed metastasis over a period of 12–25 months. Circulating VEGF levels quantified by enzyme-linked immunosorbent assay were found to be elevated in patients with primary or metastatic melanoma compared to a control group ( P<0.001), but no significant difference occurred between primary and metastatic melanoma. The follow-up of patients who developed metastasis showed high initial VEGF levels (in five out nine cases) which remained increased with the course of the disease. It is conceivable that increased VEGF levels reflect an intense activation of the host immune system but the variations in the concentration of circulating VEGF were not considered as an indicator of disease evolution in malignant melanoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
